利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

142 条记录 (耗时 0.033 秒)

    Drug Delivery of a Cox Inhibitor from Embolic Agents
    51.
    发明申请
    Drug Delivery of a Cox Inhibitor from Embolic Agents 审中-公开
    来自栓塞剂的Cox抑制剂的药物递送

    公开(公告)号：US20070281028A1

    公开(公告)日：2007-12-06

    申请号：US11573172

    申请日：2005-08-04

    申请人： Andrew Lewis ,  Peter Stratford ,  Maria Gonzalez Fajardo ,  Hind Hassan Sid Goreish

    发明人： Andrew Lewis ,  Peter Stratford ,  Maria Gonzalez Fajardo ,  Hind Hassan Sid Goreish

    IPC分类号： A61K31/415 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/42 ,  A61K45/00 ,  A61P35/00 ,  A61K9/00 ,  A61K31/54 ,  A61K31/21 ,  A61K31/341 ,  A61K31/40

    CPC分类号： A61K9/1635 ,  A61K31/19

    摘要： A pharmaceutical composition for malignant tumour embolisation comprises a polymer and, associated with the polymer in a releasable form, a COX inhibitor, e.g. a non-steroidal anti inflammatory drug, such as ibuprofen. The polymer is preferably-in particulate form, such as in the form of microspheres. A suitable polymer is a crosslinked polyvinyl alcohol polymer formed by the copolymerisation of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of malignant tumours, leading to tumour necrosis or ischaemia, with anti-angiogenic effects, promotion of apoptosis, decrease in invasiveness of tumour cells and resultant tumour regression.

    摘要翻译： 用于恶性肿瘤栓塞的药物组合物包含聚合物，并且与可释放形式的聚合物相关联，例如COX抑制剂。 非甾体抗炎药，如布洛芬。 聚合物优选为颗粒形式，例如以微球的形式。 合适的聚合物是通过PVA大分子单体与其它烯属不饱和单体的共聚形成的交联聚乙烯醇聚合物。 该组合物为恶性肿瘤的症状提供协同治疗，导致肿瘤坏死或局部缺血，具有抗血管生成作用，促进细胞凋亡，降低肿瘤细胞的侵袭性并导致肿瘤消退。

    Zwitterionic polymers
    53.
    发明申请
    Zwitterionic polymers 有权

    公开(公告)号：US20050159556A1

    公开(公告)日：2005-07-21

    申请号：US11025968

    申请日：2005-01-03

    申请人： Andrew Lewis ,  Sean Willis ,  Steven Armes ,  Emma Lobb ,  Yinghua Ma

    发明人： Andrew Lewis ,  Sean Willis ,  Steven Armes ,  Emma Lobb ,  Yinghua Ma

    IPC分类号： A61K9/10 ,  A61K47/32 ,  C08F4/40 ,  C08F20/22 ,  C08F246/00 ,  C08F293/00

    CPC分类号： C08F4/40 ,  C08F246/00 ,  C08F293/005 ,  C08F2438/01

    摘要： Polymers may be made from zwitterionic monomers having controlled architectures and molecular weights, using living polymerisations such as group or atom transfer radical polymerisation. For instance polymers may be formed by atom transfer radical polymerisation using a copper chloride catalyst, a ligand which is water soluble, and a water soluble tertiary alkyl halide initiator to form homopolymers having controlled polydispersities of less than 1.5 and block copolymers with other hydrophilic or hydrophobic monomers. One suitable zwitterionic monomer is 2-methacryloyloxy-2′-trimethylammoniumethyl phosphate inner salt. The block copolymers may spontaneously form micelles, believed to have zwitterionic, for instance phosphorylcholine, groups at the external surface, which may be useful as drug delivery systems with improved biocompatibility.

    Polymers and polymerisation processes
    54.
    发明申请
    Polymers and polymerisation processes 有权
    聚合物和聚合过程

    公开(公告)号：US20040236013A1

    公开(公告)日：2004-11-25

    申请号：US10872362

    申请日：2004-06-22

    申请人： BIOCOMPATIBLES UK LIMITED

    发明人： Andrew Lennard Lewis ,  Laurence Gerald Hughes

    IPC分类号： C08F002/16

    CPC分类号： C08F246/00 ,  Y10T428/31935

    摘要： Emulsion polymerisations are described in which the monomers include an ethylenically unsaturated ammonium phosphate ester monomer. The processes may be conducted with high total solids, to produce a polymer latex having a solids content in the range 20 to 60%, for instance in the range 25 to 50% by weight. Preferably comonomers include lower alkyl and higher alkyl methacrylate selected to give desirable glass transition temperatures and coalescing films, zwitterionic comonomers, polyethoxylated comonomers to confer desired biocompatibility and latex stability as well as good wetting for a film formed of the polymer and may contain crosslinking monomers, reactive monomers, anionic monomers and/or cationic monomers. The latexes are stable, even when the process is carried out in the substantial absence of non-polymerisable emmulsifier. Coatings formed from the latexes containing zwitterionic comonomer have good biocompatibilising properties.

    摘要翻译： 描述了乳液聚合，其中单体包括烯属不饱和磷酸铵酯单体。 该方法可以以高总固体进行，以产生固体含量在20至60％范围内，例如25至50重量％范围内的聚合物胶乳。 共聚单体优选包括低级烷基和高级烷基甲基丙烯酸酯，其选择为提供所需的玻璃化转变温度和聚结膜，两性离子共聚单体，聚乙氧基化共聚单体以赋予所需的生物相容性和胶乳稳定性以及由聚合物形成的膜的良好润湿性并且可含有交联单体， 反应性单体，阴离子单体和/或阳离子单体。 即使在基本不存在不可聚合的乳化剂的情况下进行该乳液，胶乳也是稳定的。 由含有两性离子共聚单体的胶乳形成的涂层具有良好的生物相容性。

    Coated implants
    55.
    发明申请
    Coated implants 审中-公开
    涂层植入物

    公开(公告)号：US20040197585A1

    公开(公告)日：2004-10-07

    申请号：US10700548

    申请日：2003-11-05

    申请人： BIOCOMPATIBLES UK LIMITED

    发明人： Laurence Gerald Hughes ,  Terrence Albert Vick ,  Jin Hai Wang

    IPC分类号： B05D003/00

    CPC分类号： A61L31/16 ,  A61L27/34 ,  A61L27/54 ,  A61L31/043 ,  A61L31/10 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/258 ,  A61L2300/606 ,  Y10T428/31855 ,  C08L101/02

    摘要： An implant, usually a stent, has a coating of a cross-linked water swellable polymer matrix preferably having a dry thickness of at least 0.1 nullm, and a pharmaceutically active compound, the polymer having pendant cationic and pendant zwitterionic groups. The active is usually an anionic compound such as a nucleic acid. The polymer is peferably formed from 2-methacyloy-loxyethyl-2null-trimethylammoniumethyl phosphate inner salt, trialkylammoniumalkyl(meth)acrylate and a cross-linkable monomer such as null-(trialkoxysilyl)alkyl(meth)acrylate, optionally with a termonomer such as a higher alkyl (meth)acrylate. The stent is coated with polymer, cross-linked then contacted with a solution or dispersion of active compound in a solvent which swells the polymer whereby the active is absorbed into the polymer matrix. The stent is delivered by usual means into a body lumen and the actives released over an extended period of time into the wall of the lumen and/or fluid flowing therein.

    摘要翻译： 植入物（通常为支架）具有优选具有至少0.1μm的干燥厚度的交联的可水溶胀性聚合物基质的涂层和具有阳离子阳离子和侧基两性离子基团的药学活性化合物。 活性剂通常是阴离子化合物如核酸。 聚合物由2-甲基氰基合成 - 羟乙基-2'-三甲基铵乙基磷酸酯内盐，（甲基）丙烯酸三烷基铵烷基酯和（甲基）丙烯酸ω-（三烷氧基甲硅烷基）烷基酯等可交联单体任选地与三 （甲基）丙烯酸高级烷基酯。 将支架涂覆聚合物，然后交联，然后与活性化合物的溶液或分散体在溶胀聚合物的溶剂中接触，由此活性物质被吸收到聚合物基质中。 支架通过常规手段输送到体腔中，并且活动物在延长的时间段内释放到内腔的壁中和/或在其中流动的流体。

    DUAL STAGE CRYOCOOLER
    58.
    发明公开
    DUAL STAGE CRYOCOOLER 审中-公开

    公开(公告)号：US20230389975A1

    公开(公告)日：2023-12-07

    申请号：US18236312

    申请日：2023-08-21

    申请人： Biocompatibles UK Limited

    发明人： Satish Ramadhyani ,  Graig Kveen ,  Harishankar Natesan

    IPC分类号： A61B18/02

    CPC分类号： A61B18/02 ,  A61B2018/00041

    摘要： A cryoablation tool has a primary fluid circuit for cryogenically cooling or heating tissue surrounding the distal portion of the cryoablation tool. The primary fluid circuit has a primary-primary heat exchanger facilitating recuperative heat exchange between a high pressure stream of a primary fluid and a low pressure stream of the primary fluid. The cryoablation tool has a secondary fluid circuit having a secondary-secondary heat exchanger for permitting recuperative heat exchange between a high pressure stream of a secondary fluid and a low pressure stream of the secondary fluid. The secondary fluid circuit also has a primary-secondary heat exchanger permitting heat exchange between the high pressure stream of the primary fluid and the low pressure stream of the secondary fluid.

    MULTI-WAY CONNECTOR
    59.
    发明申请
    MULTI-WAY CONNECTOR 有权

    公开(公告)号：US20220090690A1

    公开(公告)日：2022-03-24

    申请号：US17473339

    申请日：2021-09-13

    申请人： BIOCOMPATIBLES UK LIMITED

    发明人： Scott McGhee ,  David Burnett ,  Martina Marti ,  Joe Neale ,  Jonathan Vince

    IPC分类号： F16K11/085 ,  F16K31/60 ,  F16K27/06

    摘要： One aspect of the present disclosure pertains to a connector for conveying a suspension of particles through a system, comprising: a housing (10) comprising an internal cavity (12) and a first passageway (14) for conveying fluid; two or more inlet conduits (16a, 16b, 16c, 16d) formed in the housing and arranged radially with respect to a longitudinal axis of the first passageway; and a rotatable component (18) received in the internal cavity of the housing and rotatable about the longitudinal axis of the first passageway such that a continuous flow path can be established between the first passageway and a selected inlet conduit; wherein an angle between each of the inlet conduits and the first passageway (22) is greater than 90 degrees. Other aspects pertain to systems that employ such a connector and to methods of using such systems.